A free-to-attend 1-day symposium that will cover innovative approaches to preclinical translational models in immuno-oncology.

Symposium organised by Immundnz Ltd

Immuno-oncology is still one of the hot topics in cancer research. The development of cancer immunotherapies requires appropriate and innovative preclinical models and technologies. New cellular models such as CAR-T, phagocytes, cytotoxic cells and dendritic cells are immunomodulatory targets in cutting edge cancer research as well as cell signalling checkpoints. Immundnz will organise a free-to-attend 1-day symposium at the Alderley Park that will cover innovative approaches to preclinical translational models and target areas in immuno-oncology.

Preliminary program:

• Angeliki Malliri (CRUK, UK) – Cell signalling in cancer

• Sean Hammond (Apconix, UK) - Checkpoint inhibitors

• Theo Luider (Erasmus Medical Center, Netherlands) – Proteomics-based biomarkers in immuno-oncology

• Monique van Scherpenzeel (GlycoMScan, Netherlands) - Protein glycosylation in immuno-oncology

• Nils Hijlkema (HUB Organoids, Netherlands) - Patient-derived organoids to predict cancer patient response to treatment

• Wynand Alkema (TenWise and Hanze University, Netherlands) – AI and text mining in immuno-oncology

• Charlotte Wuyts (InnoSer, Belgium/Netherlands) – In vivo immuno-oncology models

• Masih Alam (Immundnz, UK) – Translational in vitro immunology models

More speakers to follow.

Free to attend, including networking lunch.

Tours to be provided after lunch

Symposium will include suppliers’ exhibits.